Winton Group LTD Uni Qure N.V. Transaction History

Winton Group LTD

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$13.15 - $20.45 $40,988 - $63,742	-3,117 Reduced 4.59%	64,788 $1.21 Million
Q1 2022 May 11, 2022	BUY	$14.54 - $21.5 $286,932 - $424,281	19,734 Added 40.97%	67,905 $1.23 Million
Q4 2021 Feb 10, 2022	BUY	$20.24 - $36.01 $490,152 - $872,054	24,217 Added 101.1%	48,171 $999,000
Q3 2021 Oct 28, 2021	BUY	$26.01 - $38.22 $290,947 - $427,528	11,186 Added 87.61%	23,954 $767,000
Q2 2021 Aug 10, 2021	SELL	$29.97 - $37.17 $166,992 - $207,111	-5,572 Reduced 30.38%	12,768 $393,000
Q1 2021 Jul 21, 2021	BUY	$29.24 - $42.03 $183,919 - $264,368	6,290 Added 52.2%	18,340 $618,000
Q4 2020 Feb 12, 2021	SELL	$35.35 - $50.67 $519,751 - $745,001	-14,703 Reduced 54.96%	12,050 $435,000
Q3 2020 Oct 30, 2020	BUY	$35.98 - $47.66 $962,572 - $1.28 Million	26,753 New	26,753 $985,000
Q1 2020 May 11, 2020	SELL	$40.01 - $73.97 $1.2 Million - $2.22 Million	-30,025 Closed	0 $0
Q4 2019 Feb 13, 2020	BUY	$37.13 - $74.62 $903,818 - $1.82 Million	24,342 Added 428.33%	30,025 $2.15 Million
Q3 2019 Nov 08, 2019	BUY	$39.36 - $76.8 $223,682 - $436,454	5,683 New	5,683 $224,000

153

41M

925K

617K

Ticker QURE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,729,100
Market Cap $266M
Description
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy th...

Get notified when there are updates to the investment portfolio of Winton Group LTD, based on Form 13F filings with the SEC.

Stay updated on Winton Group LTD with notifications on news.